Efficacy of CBS9106 in human MM xenograft models. Subcutaneous tumor growth curves (A) and the body weight change (B) of subcutaneous xenograft model of RPMI-8226 (n = 8). Mice were treated orally with vehicle (Gum Arabic, ●) or CBS9106 (31.25 mg/kg, 5 times weekly, □; 62.5 mg/kg, 5 times weekly, ▵; or 125 mg/kg, 3 times weekly, ○) for 2 weeks. (C) Tumors from RPMI-8226 cell xenografts were harvested at 24 or 48 hours from the mice treated orally with vehicle (Gum Arabic, Gum) or CBS9106 (125 mg/kg, A-C). Protein extracts prepared from the tumors were analyzed by immunoblotting to detect indicated proteins. (D) Survival analysis of the MM.1S xenograft model mice (n = 10) with oral CBS9106 treatment (125 mg/kg, 3 times weekly, dotted line) for 2 weeks. (E) Body weight change for panel D. Error bars represent SE.